Vifor Pharma


Partner Akebia’s drug hits a roadblock

07/09/20 -"Surprisingly, Akebia’s oral HIF-PHI drug, Vadadustat, has shown heart safety concerns in a phase III study for non-dialysis CKD-anaemic patients. Although partner Vifor isn’t impacted directly – it ..."

Pages
65
Language
English
Published on
07/09/20
You may also be interested by these reports :
26/10/20
The acquisition of Asklepios BioPharmaceutical (AskBio), while not a bargain, is a great move into the really hot topic of gene therapy. Based on the ...

23/10/20
While Somatuline lost pace in Q3 – due to lower patient diagnoses amidst the pandemic – Cabometyx witnessed an acceleration on the back of a solid ...

22/10/20
The building block of any European equity portfolio, Pharmas, has lost its bearings. Markets, which are ready to pay for anything that smacks of ...

16/10/20
After a disappointing Q2 (-4% CER sales growth), Roche had some respite in Q3 (+1%) – though below expectations, largely driven by diagnostics due to ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO